Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
|Videos|May 19, 2022
Current Trends in Suicide: APA Preview With the Chief Medical Officer of the AFSP
Author(s)Christine Yu Moutier, MD
Christine Yu Moutier, MD, is excited to see you at the APA Annual Meeting in New Orleans!
Advertisement
Christine Yu Moutier, MD, the Chief Medical Officer for the AFSP, is excited to be attending APA's Annual Meeting in New Orleans. What is she looking forward to? Find out here.
Be sure not to miss her talk,
Dr Moutier is chief medical officer of the American Foundation for Suicide Prevention, New York, NY.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
What Clinicians Need to Know About Postpartum Psychosis
3
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5